Vital Therapies

Vital Therapies, Inc. is a biotherapeutic company focused on developing a cell-based therapy targeting the treatment of acute liver failure. Our product candidate, the ELAD® System, or ELAD, is a bio-artificial liver therapy that operates outside the body, or extracorporeal, and is designed with the proposed intent to allow the patient’s own liver to regenerate to a healthy state, or to stabilize the patient until liver transplant. ELAD is an allogeneic cellular therapy system incorporating our human liver-derived C3A cells contained in four hollow fiber cartridges that are combined with a single use customized disposable set and a reusable bedside unit. Data from ELAD clinical studies has shown trends that may indicate a potential to increase survival rates in patients with acute liver failure. ELAD has received orphan designation in the United States and Europe for the treatment of acute liver failure. Prior to the initiation of our ongoing Phase III clinical trial program, more than 150 subjects have received ELAD therapy in seven clinical trials and through a compassionate use program, which we believe collectively suggests a promising therapeutic profile. We are currently initiating three Phase III clinical trials in various acute liver failure conditions. In March 2013, we initiated VTI-208, a Phase III randomized, controlled clinical trial in 200 subjects with alcohol-induced liver decompensation. In the fourth quarter of 2013, we intend to initiate two additional Phase III randomized controlled trials, VTI-210, in 120 subjects with acute alcoholic hepatitis, and VTI-212, in 126 subjects with fulminant hepatic failure.

Type
Public
HQ
San Diego, US
Founded
2003
Size (employees)
87 (est)+12%
Vital Therapies was founded in 2003 and is headquartered in San Diego, US

Key People at Vital Therapies

John Brotherton

John Brotherton

VP, Research & Developmen
Shapour Asslani

Shapour Asslani

VP, Quality Control & Quality Assurance
Duane Nash

Duane Nash

EVP
Dar He

Dar He

Vice President, International Operations
Robert A. Ashley

Robert A. Ashley

Chief Operating Officer, Executive Vice President

Vital Therapies Office Locations

Vital Therapies has an office in San Diego
San Diego, US (HQ)
15010 Avenue Of Science

Vital Therapies Data and Metrics

Vital Therapies Financial Metrics

USD

Net income (FY, 2016)

(41 m)

EBIT (FY, 2016)

(41.3 m)

Market capitalization (28-Jun-2017)

126.6 m

Closing share price (28-Jun-2017)

3

Cash (31-Dec-2016)

60 m
Vital Therapies's current market capitalization is $126.6 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

39.5 m39.8 m30 m

General and administrative expense

10.9 m12.3 m11.2 m

Operating expense total

50.3 m52.1 m41.3 m

EBIT

(50.3 m)(52.1 m)(41.3 m)

Interest expense

(413 k)

Interest income

19 k58 k284 k

Net Income

(47.7 m)(52 m)(41 m)
USDFY, 2014FY, 2015FY, 2016

Cash

102.2 m83.4 m60 m

Inventories

1.3 m30.2 m20.8 m

Current Assets

104.8 m85.1 m61.5 m

PP&E

3.1 m3.8 m2.5 m

Total Assets

108.1 m89.1 m64 m

Accounts Payable

1.2 m1.2 m780 k

Current Liabilities

10.3 m6.7 m5.5 m

Additional Paid-in Capital

248.3 m285.1 m302.2 m

Retained Earnings

(150.8 m)(202.9 m)(243.8 m)

Total Equity

97.6 m82.3 m58.4 m

Financial Leverage

1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(47.7 m)(52 m)(41 m)

Depreciation and Amortization

1.1 m1.3 m1.8 m

Inventories

(6.5 m)

Accounts Payable

46 k281 k(459 k)

Cash From Operating Activities

(40.8 m)(50 m)(35.8 m)

Purchases of PP&E

(1.4 m)(2.3 m)(556 k)

Cash From Investing Activities

(2 m)(1.3 m)(21 k)

Cash From Financing Activities

106.9 m32.4 m12.4 m

Interest Paid

32 k
Y, 2016

Financial Leverage

1.1 x

Vital Therapies Market Value History

Vital Therapies Company Life and Culture

You may also be interested in